BMJ Case Rep
Medical Gastroenterology, Dr DY Patil Medical College, Hospital & Research Center, Dr. DY Patil Vidyapeeth (Deemed to be University), Pimpri, Pune, Maharashtra, India.
Published: February 2025
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory condition with a varied clinical presentation. It can involve multiple organ systems and has the potential to impact any part of the gastrointestinal tract. Intestinal pseudo-obstruction (IPO) is a rare yet severe gastrointestinal manifestation of SLE. Two-thirds of SLE patients with IPO present with concomitant hydroureteronephrosis. This report details the case of a young woman who presented with IPO as the initial manifestation of SLE. The presence of proteinuria with bilateral hydroureteronephrosis in this patient with IPO prompted a trail of investigations that led to the diagnosis of SLE. This diagnosis mitigated the need for surgery, as the patient responded to immunosuppressive therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bcr-2024-263491 | DOI Listing |
Lupus Sci Med
March 2025
Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
Objective: The objective of this research is to identify metabolic markers associated with successful treatment by evaluating the effect of mesenchymal stem cell transplantation (MSCT) on the metabolic profiles of patients with SLE.
Methods: Plasma samples were collected from 20 patients with SLE before and after MSCT. Principal component analysis (PCA) was used to distinguish pretreatment and post-treatment groups and pathway analysis for identifying involved metabolic pathways.
Exp Cell Res
March 2025
Central Labs, King Khalid University, AlQura'a, Abha, Saudi Arabia; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. Electronic address:
CS1 (SLAMF7), a pivotal immune receptor, plays a dual role in modulating immune responses in autoimmune diseases and cancer. In autoimmunity, aberrant CS1 signaling contributes to the activation of autoreactive lymphocytes, driving pathologies such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Conversely, in oncology, CS1 serves as a promising immunotherapeutic target, exemplified by the efficacy of the monoclonal antibody Elotuzumab in multiple myeloma.
View Article and Find Full Text PDFMol Immunol
March 2025
Department of Medical Laboratory, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, Hainan Province 571100, China.
Background: Systemic lupus erythematosus (SLE) was a complex autoimmune disease characterized by a spectrum of clinical and immunological manifestations, with cardiovascular disease (CVD) being a leading cause of morbidity and mortality. Endothelial dysfunction was critical in the pathogenesis of atherosclerosis and other cardiovascular complications in SLE. This study aimed to investigate the correlation between autoantibody levels and endothelial function in SLE patients using ultrasound and serum biomarkers.
View Article and Find Full Text PDFClin Exp Rheumatol
March 2025
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
This review highlights key advancements in systemic lupus erythematosus (SLE) research during 2024, covering pathogenesis, novel therapies, biomarkers, and clinical outcomes. Notable findings include new insights into immune dysregulation, promising therapeutic targets, and real-world data confirming the efficacy of anifrolumab and belimumab. Advances in biomarkers enhance disease monitoring, while multidisciplinary approaches improve reproductive outcomes and quality of life.
View Article and Find Full Text PDFCell Mol Life Sci
March 2025
Institute for Physiological Chemistry, Faculty of Medicine Carl Gustav Carus, Medizinisch-Theoretisches Zentrum MTZ, Technische Universität Dresden, Fiedlerstraße 42, 01307, Dresden, Germany.
Signal peptide peptidase (SPP) is an ER-resident aspartyl intramembrane protease cleaving proteins within type II-oriented transmembrane segments. Here, we identified the tail-anchored protein Three prime repair exonuclease 1 (TREX1) as a novel substrate of SPP. Based on its DNase activity, TREX1 removes cytosolic DNA acting as a negative regulator of the DNA-sensing cGAS/STING pathway.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.